AnaptysBio Says EC Approval of Jemperli Triggers Milestone Payment
By Stephen Nakrosis
Biotechnology company AnaptysBio Inc. Friday said the European
Commission granted conditional marketing authorization to Jemperli
for certain female cancer patients, triggering a $10 million
milestone payment for the company.
The company said Jemperli is under clinical development for
solid tumors in collaboration with GlaxoSmithKline.
AnaptysBio said the EC gave granted conditional marketing
authorization for Jemperli, or dostarlimab, to treat women with
certain forms of advanced endometrial cancer who have progressed on
or following prior treatment with a platinum containing
AnaptysBio said the approval makes dostarlimab the first
anti-PD-1 therapy available for endometrial cancer in Europe.
The company said it generated Jemperli using its proprietary
somatic hypermutation antibody platform, adding it was subsequently
developed by Tesaro, Inc., now a part of GSK, under a collaboration
AnaptysBio is in line for additional milestone payments and is
due to receive 8% to 25% royalty on global net sales of
dostarlimab, it said.
Earlier this month, AnaptysBio said, it earned a $20 million
milestone payment as a result of approval by the U.S. Food and Drug
Administration for Jemperli in endometrial cancer.
--Write to Stephen Nakrosis at email@example.com
(END) Dow Jones Newswires
April 23, 2021 11:51 ET (15:51 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.